Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Direct-Acting Antiviral Drugs in Patients with Haemoglobinophaties and Chronic Hepatitis C Infection

Antonio Piga, MD, Paolo Rigano, MD, Raffaella Origa, MD, M. Domenica Cappellini, MD, Valeria Pinto, MD, Immacolata Tartaglione, MD, Aldo Filosa, MD, Domenico D'Ascola, MD, Vito Di Marco, Gian Luca Forni, MD

Blood (2016) 128 (22): 3627.

https://doi.org/10.1182/blood.V128.22.3627.3627

Published: 2016

Journal Articles

Optimizing Iron Chelation Therapy with Deferasirox for Non-Transfusion-Dependent Thalassemia Patients: 1-Year Results from the Phase IV, Open-Label Thetis Study

Ali T Taher, M Domenica Cappellini, Yesim Aydinok, John B. Porter, Zeynep Karakas, Vip Viprakasit, Noppadol Siritanaratkul, Antonis Kattamis, Candace Wang, Zewen Zhu, Victor Joaquin, Marie José Uwamahoro, Yong-Rong Lai

Blood (2015) 126 (23): 2153.

https://doi.org/10.1182/blood.V126.23.2153.2153

Published: 2015

Journal Articles

Correlation of Hepatocyte Iron Score and Liver Iron Ratio with Alanine Aminotransferase in Patients with Beta Thalassemia Receiving Iron Chelation Therapy for at Least 3 Years

M Domenica Cappellini, Mohamed Bejaoui, Silverio Perrotta, MD, Leyla Agaoglu, Antonis Kattamis, Jackie Han, Ali El-Ali, John B Porter

Blood (2015) 126 (23): 2156.

https://doi.org/10.1182/blood.V126.23.2156.2156

Published: 2015

Journal Articles

Efficacy and Safety of Deferasirox in Chinese Patients with Non-Transfusion-Dependent Thalassemia: 1-Year Results from the Thetis Study

Yong-Rong Lai, Rong Rong Liu, M Domenica Cappellini, Yesim Aydinok, John B Porter, Zewen Zhu, Candace Wang, Xue Qi, Ali T Taher

Blood (2015) 126 (23): 4570.

https://doi.org/10.1182/blood.V126.23.4570.4570

Published: 2015

Journal Articles

Efficacy and Safety of Deferasirox Across Underlying Non-Transfusion-Dependent Thalassemia Syndromes: 1-Year Results from the Thetis Study

M Domenica Cappellini, Vip Viprakasit, Yesim Aydinok, John B Porter, Yong-Rong Lai, Noppadol Siritanaratkul, Zeynep Karakas, Antonis Kattamis, Candace Wang, Zewen Zhu, Felicity Schaefer, Ali T Taher

Blood (2015) 126 (23): 3366.

https://doi.org/10.1182/blood.V126.23.3366.3366

Published: 2015

Journal Articles

Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload

Yesim Aydinok, Antonis Kattamis, M. Domenica Cappellini, Amal El-Beshlawy, Raffaella Origa, Mohsen Elalfy, Yurdanur Kilinç, Silverio Perrotta, Zeynep Karakas, Vip Viprakasit, Dany Habr, Niculae Constantinovici, Junwu Shen, John B. Porter

Blood (2015) 125 (25): 3868–3877.

https://doi.org/10.1182/blood-2014-07-586677

Published: 2015

Includes: Supplemental data

Journal Articles

Multivariate Analysis Evaluating Potential Predictors of Cardiac T2* Where Cardiac Magnetic Resonance Imaging (CMR) Availability Is Limited

John B Porter, MD, Ali T Taher, MD PhD, Yesim Aydinok, MD, Amal El-Beshlawy, MD/Professor, Mohsen El-Alfy, MD, Ali El-Ali, MD, Subhashish Chakravarty, PhD, M Domenica Cappellini, MD

Blood (2014) 124 (21): 1366.

https://doi.org/10.1182/blood.V124.21.1366.1366

Published: 2014

Journal Articles

Relative Trends in Myocardial T2* Versus Myocardial Iron Concentration As Representations of Myocardial Iron Chelation Efficacy in Patients with β Thalassemia Major Treated with Deferasirox for up to 3 Years

John B Porter, MD, Ali T Taher, MD, Yesim Aydinok, MD, Amal El-Beshlawy, MD/Professor, Mohsen Elalfy, MD, Ali El-Ali, MD, Nathalie Barbier, M Domenica Cappellini, MD

Blood (2014) 124 (21): 4040.

https://doi.org/10.1182/blood.V124.21.4040.4040

Published: 2014

Journal Articles

Deferasirox–Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION)

Yesim Aydinok, MD, Antonis Kattamis, MD, M Domenica Cappellini, MD, Amal El-Beshlawy, MD, Raffaella Origa, MD, Mohsen Elalfy, MD, Yurdanur Kilinç, MD, Silverio Perrotta, MD, Zeynep Karakas, MD, Vip Viprakasit, MD, Dany Habr, MD, Antje Wegener, MD, Junwu Shen, PhD, John B Porter, MD

Blood (2013) 122 (21): 2257.

https://doi.org/10.1182/blood.V122.21.2257.2257

Published: 2013

Journal Articles

Two-Year Renal Hemodynamic Effects of Deferasirox in Patients with Transfusion-Dependent β-Thalassemia

Antonio Piga, MD, Silvia Fracchia, MD, Maria Eliana Lai, MD, M Domenica Cappellini, MD, Dany Habr, MD, Antje Wegener, MD, Emmanuel Bouillaud, MSc, Gian Luca Forni, MD

Blood (2012) 120 (21): 3257.

https://doi.org/10.1182/blood.V120.21.3257.3257

Published: 2012

Journal Articles

Deferasirox Continues to Reduce Iron Overload in Non-Transfusion-Dependent Thalassemia: A One-Year, Open-Label Extension to a One-Year, Randomized, Double-Blind, Placebo-Controlled Study (THALASSA)

Ali T Taher, MD, John B Porter, MD, Vip Viprakasit, MD, DPhil, Antonis Kattamis, MD, Suporn Chuncharunee, MD, Pranee Sutcharitchan, MD, Noppadol Siritanaratkul, MD, Renzo Galanello, MD, Zeynep Karakas, MD, Tomasz Lawniczek, MD, Dany Habr, MD, Jacqueline Ros, PhD, Zewen Zhu, M Domenica Cappellini, MD

Blood (2012) 120 (21): 3258.

https://doi.org/10.1182/blood.V120.21.3258.3258

Published: 2012

Journal Articles

Serum Ferritin, Labile Plasma Iron and Transferrin Saturation: Comparison Between Underlying Anemias with Transfusional Iron Overload Before and After Treatment with Deferasirox.

John B Porter, MD, Mohsen Elalfy, MD, Vip Viprakasit, MD, DPhil, Stephane Giraudier, MD, Lee Lee Chan, MD, Yongrong Lai, MD, Ali El-Ali, MD, Nicolas Martin, MS, M Domenica Cappellini, MD

Blood (2012) 120 (21): 2126.

https://doi.org/10.1182/blood.V120.21.2126.2126

Published: 2012

Journal Articles

Deferasirox Treatment for up to 3 Years in Iron-Overloaded Pediatric Patients Reduces Serum Ferritin with a Manageable Safety Profile

Amal El-Beshlawy, MD, Mohsen Elalfy, MD, Lee Lee Chan, MD, Yongrong Lai, MD, Kai-Hsin Lin, MD, Yesim Aydinok, MD, Renzo Galanello, MD, Ali El-Ali, MD, Nicolas Martin, MS, M Domenica Cappellini, MD

Blood (2012) 120 (21): 1028.

https://doi.org/10.1182/blood.V120.21.1028.1028

Published: 2012

Journal Articles

Concomitant Medications and Gastrointestinal Events in Thalassemia and MDS Patients Receiving Deferasirox for Transfusional Iron Overload: Data From the EPIC Study

M Domenica Cappellini, MD, Amal El-Beshlawy, MD, John B Porter, MD, Antonis Kattamis, MD, PhD, Kerry Taylor, MD, Christian Rose, Vernon J Louw, MD, Ali El-Ali, MD, Nicolas Martin, MS, Norbert Gattermann, MD

Blood (2012) 120 (21): 5182.

https://doi.org/10.1182/blood.V120.21.5182.5182

Published: 2012

Journal Articles

Deferasirox Significantly Reduces Liver Iron Concentration In Non-Transfusion-Dependent Thalassemia Patients with Iron Overload: Results From the 1-Year Randomized, Double-Blind, Placebo-Controlled Phase II THALASSA Study

Ali T Taher, MD, John B. Porter, MD, Vip Viprakasit, MD; DPhil, Antonis Kattamis, MD, Suporn Chuncharunee, MD, Pranee Sutcharitchan, MD, Noppodol Siritanaratkul, MD, Renzo Galanello, MD, Zeynep Karakas, MD, Tomasz Lawniczek, MD, Jacqueline Ros, PhD, Yiyun Zhang, Dany Habr, MD, M. Domenica Cappellini, MD

Blood (2011) 118 (21): 902.

https://doi.org/10.1182/blood.V118.21.902.902

Published: 2011

Journal Articles

1-Year Results From A Prospective Randomized Trial Comparing Phlebotomy with Deferasirox for the Treatment of Iron Overload in Pediatric Patients with Thalassemia Major Following Curative Stem Cell Transplantation

Adlette Inati, MD, Nada Sbeiti, MD, Evelyne Khoriaty, MD, M Domenica Cappellini, MD, Suzanne Koussa, MD, Therese Abi Nasr, MD, Khaled M Musallam, MD, Ali T Taher, MD

Blood (2011) 118 (21): 904.

https://doi.org/10.1182/blood.V118.21.904.904

Published: 2011

Journal Articles

Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up

M. Domenica Cappellini, Mohamed Bejaoui, Leyla Agaoglu, Duran Canatan, Marcello Capra, Alan Cohen, Guillermo Drelichman, Marina Economou, Slaheddine Fattoum, Antonis Kattamis, Yurdanur Kilinc, Silverio Perrotta, Antonio Piga, John B. Porter, Louis Griffel, Victor Dong, Joan Clark, Yesim Aydinok

Blood (2011) 118 (4): 884–893.

https://doi.org/10.1182/blood-2010-11-316646

Published: 2011

Includes: Supplemental data

Journal Articles

Safety of Deferasirox (Exjade®) in Myelodysplastic Syndromes (MDS) and Non-MDS Patients with Transfusional Iron Overload: A Pooled Analysis Focusing On Renal Function.

Mathias Schmid, M. Domenica Cappellini, John B. Porter, Peter L. Greenberg, MD, Tomasz Lawniczek, Sabine Glaser, Victor Dong, Norbert Gattermann, MD, PhD

Blood (2009) 114 (22): 1768.

https://doi.org/10.1182/blood.V114.22.1768.1768

Published: 2009

Journal Articles

Improved Patient Satisfaction, Adherence and Health-Related Quality of Life with Deferasirox (Exjade®) in β-Thalassemia Patients Previously Receiving Other Iron Chelation Therapies.

John B. Porter, Miranda Athanasiou-Metaxa, Donald K. Bowden, Jacques Troncy, Dany Habr, Gabor Domokos, Bernard Roubert, Diana Rofail, Adam Gater, Jean-François Baladi, M. Domenica Cappellini

Blood (2009) 114 (22): 2486.

https://doi.org/10.1182/blood.V114.22.2486.2486

Published: 2009

Journal Articles

Deferasirox (Exjade®) ≥30 Mg/Kg/Day Is Effective in Reducing Iron Burden in Thalassemia Major Patients Previously Chelated with Monotherapy or Combination Therapy.

Ali Taher, Mohsen Saleh Elalfy, Amal El-Beshlawy, Dunhua Zhou, Lee Lee Chan, Chi-Kong Li, Kai-Hsin Lin, John B. Porter, Pranee Sutcharitcharan, Dany Habr, Gabor Domokos, Bernard Roubert, M. Domenica Cappellini

Blood (2009) 114 (22): 4058.

https://doi.org/10.1182/blood.V114.22.4058.4058

Published: 2009

NARROW

Safety and Efficacy of Direct-Acting Antiviral Drugs in Patients with Haemoglobinophaties and Chronic Hepatitis C Infection

Optimizing Iron Chelation Therapy with Deferasirox for Non-Transfusion-Dependent Thalassemia Patients: 1-Year Results from the Phase IV, Open-Label Thetis Study

Correlation of Hepatocyte Iron Score and Liver Iron Ratio with Alanine Aminotransferase in Patients with Beta Thalassemia Receiving Iron Chelation Therapy for at Least 3 Years

Efficacy and Safety of Deferasirox in Chinese Patients with Non-Transfusion-Dependent Thalassemia: 1-Year Results from the Thetis Study

Efficacy and Safety of Deferasirox Across Underlying Non-Transfusion-Dependent Thalassemia Syndromes: 1-Year Results from the Thetis Study

Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload

Multivariate Analysis Evaluating Potential Predictors of Cardiac T2* Where Cardiac Magnetic Resonance Imaging (CMR) Availability Is Limited

Relative Trends in Myocardial T2* Versus Myocardial Iron Concentration As Representations of Myocardial Iron Chelation Efficacy in Patients with β Thalassemia Major Treated with Deferasirox for up to 3 Years

Deferasirox–Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION)

Two-Year Renal Hemodynamic Effects of Deferasirox in Patients with Transfusion-Dependent β-Thalassemia

Deferasirox Continues to Reduce Iron Overload in Non-Transfusion-Dependent Thalassemia: A One-Year, Open-Label Extension to a One-Year, Randomized, Double-Blind, Placebo-Controlled Study (THALASSA)

Serum Ferritin, Labile Plasma Iron and Transferrin Saturation: Comparison Between Underlying Anemias with Transfusional Iron Overload Before and After Treatment with Deferasirox.

Deferasirox Treatment for up to 3 Years in Iron-Overloaded Pediatric Patients Reduces Serum Ferritin with a Manageable Safety Profile

Concomitant Medications and Gastrointestinal Events in Thalassemia and MDS Patients Receiving Deferasirox for Transfusional Iron Overload: Data From the EPIC Study

Deferasirox Significantly Reduces Liver Iron Concentration In Non-Transfusion-Dependent Thalassemia Patients with Iron Overload: Results From the 1-Year Randomized, Double-Blind, Placebo-Controlled Phase II THALASSA Study

1-Year Results From A Prospective Randomized Trial Comparing Phlebotomy with Deferasirox for the Treatment of Iron Overload in Pediatric Patients with Thalassemia Major Following Curative Stem Cell Transplantation

Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up

Safety of Deferasirox (Exjade®) in Myelodysplastic Syndromes (MDS) and Non-MDS Patients with Transfusional Iron Overload: A Pooled Analysis Focusing On Renal Function.

Improved Patient Satisfaction, Adherence and Health-Related Quality of Life with Deferasirox (Exjade®) in β-Thalassemia Patients Previously Receiving Other Iron Chelation Therapies.

Deferasirox (Exjade®) ≥30 Mg/Kg/Day Is Effective in Reducing Iron Burden in Thalassemia Major Patients Previously Chelated with Monotherapy or Combination Therapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only